4-(3-((9-chloro-10-fluoro-3-methoxy-8H-quinazolino[4,3-b]quinazoline-2-yl)oxy)propyl)morpholine | 1347719-70-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(3-((9-chloro-10-fluoro-3-methoxy-8H-quinazolino[4,3-b]quinazoline-2-yl)oxy)propyl)morpholine
• 英文别名: 4-[3-[(9-chloro-10-fluoro-3-methoxy-8H-quinazolino[3,2-c]quinazolin-2-yl)oxy]propyl]morpholine
• CAS: 1347719-70-3
• 化学式: C₂₃H₂₄ClFN₄O₃
• 分子量: 458.92
• InChiKey: WBXNRMJJWBGJCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  58.9
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• POLYCYCLIC QUINAZOLINES, PREPARATION THEREOF, AND USE THEREOF
  申请人：Li Jianqi

  公开号：US20110288086A1

  公开（公告）日：2011-11-24

  At least one active pharmaceutical ingredient is chosen from polycyclic quinazolines of formula V, pharmaceutically acceptable salts thereof, and hydrates of the pharmaceutically acceptable salts. The active pharmaceutical ingredients disclosed may be inhibitors of protein tyrosine kinase inhibitors and/or aurora kinase. The active pharmaceutical ingredients can be used for treating cancers susceptible to treatment with protein tyrosine kinase inhibitors and/or aurora kinase inhibitors.

  至少选择一种活性药用成分来自公式V的多环喹唑啉，其药学上可接受的盐，以及药学上可接受的盐的水合物。所披露的活性药用成分可能是蛋白酪氨酸激酶抑制剂和/或极化激酶的抑制剂。这些活性药用成分可用于治疗对蛋白酪氨酸激酶抑制剂和/或极化激酶抑制剂治疗敏感的癌症。
• FUSED QUINAZOLINE DERIVATIVES AND USES THEREOF
  申请人：Shenzhen Salubris Pharmaceuticals Co., Ltd.

  公开号：EP2592083A1

  公开（公告）日：2013-05-15

  Fused quinazoline derivatives and uses thereof as protein tyrosine kinase inhibitors and aurora kinase inhibitors are disclosed. Said protein tyrosine kinase inhibitors and aurora kinase inhibitors can be used in treating cancers, leukaemia and the diseases relevant to differentiation and proliferation. Said protein tyrosine kinase and aurora kinase dual inhibitors are the compounds represented by the following general formula or salts thereof.

  本研究公开了融合喹唑啉衍生物及其作为蛋白酪氨酸激酶抑制剂和极光激酶抑制剂的用途。所述蛋白酪氨酸激酶抑制剂和极光激酶抑制剂可用于治疗癌症、白血病以及与分化和增殖有关的疾病。所述蛋白酪氨酸激酶和极光激酶双重抑制剂为下通式所代表的化合物或其盐类。